Get Oncobiologics alerts:Oncobiologics, Inc. (NASDAQ:OTLK – Free Report) – Analysts at Brookline Capital Management issued their FY2025 EPS estimates for shares of Oncobiologics in a research note issued to investors on Monday, September 29th. Brookline Capital Management also issued estimates for Oncobiologics’ Q4 2025 earnings at ($0.19) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at $0.02 EPS. Guggenheim lowered shares of Oncobiologics from a “buy” rating to a “neutral” rating in a report on Thursday, August 28th. Zacks Research downgraded Oncobiologics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 27th. Oncobiologics Stock Up 2.9%Shares of OTLK opened at $1.07 on Thursday.